Roche and Athena See the Benefit of Clinical Lab Acquisitions
Two drug companies, one large the other small, made acquisitions that highlight the role diagnostics will play in a more cost-constrained pharmaceutical environment. In Roche's acquiring National Health, it creates a player able to bundle drugs and diagnostic services together in attractively priced packages. Athena's acquisition of Genica, an esoteric testing lab specializing in CNS, boosts Athena's CNS sales force and gives the reps a series of technologically sophisticated products to sell to neurologists.
You may also be interested in...
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.